Security of the Combined Treatment of Methotrexate and Leflunomidc in Patients with Rheumatoid Arthritis

Mostrar todas las versiones(2)

Rheumatoid Arthritis (RA) is a chronic  discase leacling to functional impairrncnt and early mortality. Treatment with diseasernodifying antirheumat.ic drugs have shown to achicvc disease remission and improves its evolution. The use of combined therapy should have a biological efficacy, no increase...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Nesa, L, Gobbi, Carla Andrea, Alba, Paula, Exeni, Ida Elena, Babini, Alejandra, Albiero, Eduardo Horacio
Formato: Artículo revista
Lenguaje:Español
Publicado: Universidad Nacional Cba. Facultad de Ciencias Médicas. Secretaria de Ciencia y Tecnología 2019
Acceso en línea:https://revistas.unc.edu.ar/index.php/med/article/view/25431
Aporte de:
Revistas de la UNC de Universidad Nacional de Córdoba
id I10-R10article-25431
record_format ojs
institution Universidad Nacional de Córdoba
institution_str I-10
repository_str R-10
container_title_str Revistas de la UNC
language Español
format Artículo revista
author Nesa, L
Gobbi, Carla Andrea
Alba, Paula
Exeni, Ida Elena
Babini, Alejandra
Albiero, Eduardo Horacio
spellingShingle Nesa, L
Gobbi, Carla Andrea
Alba, Paula
Exeni, Ida Elena
Babini, Alejandra
Albiero, Eduardo Horacio
Security of the Combined Treatment of Methotrexate and Leflunomidc in Patients with Rheumatoid Arthritis
author_facet Nesa, L
Gobbi, Carla Andrea
Alba, Paula
Exeni, Ida Elena
Babini, Alejandra
Albiero, Eduardo Horacio
author_sort Nesa, L
title Security of the Combined Treatment of Methotrexate and Leflunomidc in Patients with Rheumatoid Arthritis
title_short Security of the Combined Treatment of Methotrexate and Leflunomidc in Patients with Rheumatoid Arthritis
title_full Security of the Combined Treatment of Methotrexate and Leflunomidc in Patients with Rheumatoid Arthritis
title_fullStr Security of the Combined Treatment of Methotrexate and Leflunomidc in Patients with Rheumatoid Arthritis
title_full_unstemmed Security of the Combined Treatment of Methotrexate and Leflunomidc in Patients with Rheumatoid Arthritis
title_sort security of the combined treatment of methotrexate and leflunomidc in patients with rheumatoid arthritis
description Rheumatoid Arthritis (RA) is a chronic  discase leacling to functional impairrncnt and early mortality. Treatment with diseasernodifying antirheumat.ic drugs have shown to achicvc disease remission and improves its evolution. The use of combined therapy should have a biological efficacy, no increased toxicity and have an acceptable dose interval. Also, it shoulcl begin its action quickly and he cost-effective. Aims: to assess the security of the combinen treatment withMethotrexate (MTX) and Leflunomide (LF) in patients with Rheurnatoid Arthritis (RA) and to evaluate whethcr the dose and route of MTX administration influence on the toxicity. Patients and Methocls: Patients with RA who fulfihlecl ACR entena and they attencled to the Rheumatology Unit at Córdoba Hospital in the Iast 2 years were assessed. All the patients that received combined treatment with MTX in doses from 7.5 mg to 25 mg weekly orally (PO) orintramuscularly (TM) that started LF treatment in doses of 20 mg/day due to disease activity persistericc were retrospectively assessed.Patients having at least 6 months of combined treatment were inclucled. Data ontreatment and adverse events were collected. They were evaluated at the hegirining, at 6 and 12 months of treatment. The presence of adverse events as well as the stop of combined treatment was evaluated at 6 and 12 months 01treatment. Adverse events in patients with oral and IM MTX treatment and in different doses were compared for the analyses. P<0.05 was considered significant. Results: 62 patients with a mean age of 54 were included. 89% were female and had positive rheumatoid factor and 83% had radiological erosions. Eighty eight percent were in doses of I5mg MTX, 4.9%with lomg and 2flrngattheheginning of LE treatment. Twentv four percent suffered from adverse events and 33% left the medication by 6 months. Among adverse events, 6 patients had cliarrhea, 5 increased hepatic enzymes, 3 alopecia, 3 weight loss, and2 had anemia and leucopenia. Eight patients stopped the medication in 6 months, but only 5 did because of adverse events. There was not significant statistical differcncc in adverse events hetween patients with different dose or routes of administration of MTX. Conclusions: The presence of adverse events in MTX and LF combined treatment was low and it developed dunng the first 6 months of treatment in our patients. The MTX route of administration and doses did not influence on the toxicity of the combined treatment with LF. The combinedtherapy seems to be a sale treatment option in RA patients.
publisher Universidad Nacional Cba. Facultad de Ciencias Médicas. Secretaria de Ciencia y Tecnología
publishDate 2019
url https://revistas.unc.edu.ar/index.php/med/article/view/25431
work_keys_str_mv AT nesal securityofthecombinedtreatmentofmethotrexateandleflunomidcinpatientswithrheumatoidarthritis
AT gobbicarlaandrea securityofthecombinedtreatmentofmethotrexateandleflunomidcinpatientswithrheumatoidarthritis
AT albapaula securityofthecombinedtreatmentofmethotrexateandleflunomidcinpatientswithrheumatoidarthritis
AT exeniidaelena securityofthecombinedtreatmentofmethotrexateandleflunomidcinpatientswithrheumatoidarthritis
AT babinialejandra securityofthecombinedtreatmentofmethotrexateandleflunomidcinpatientswithrheumatoidarthritis
AT albieroeduardohoracio securityofthecombinedtreatmentofmethotrexateandleflunomidcinpatientswithrheumatoidarthritis
AT nesal seguridaddeltratamientocombinadodemetotrexatoyleflunomidaenpacientesconartritisreumatoidea
AT gobbicarlaandrea seguridaddeltratamientocombinadodemetotrexatoyleflunomidaenpacientesconartritisreumatoidea
AT albapaula seguridaddeltratamientocombinadodemetotrexatoyleflunomidaenpacientesconartritisreumatoidea
AT exeniidaelena seguridaddeltratamientocombinadodemetotrexatoyleflunomidaenpacientesconartritisreumatoidea
AT babinialejandra seguridaddeltratamientocombinadodemetotrexatoyleflunomidaenpacientesconartritisreumatoidea
AT albieroeduardohoracio seguridaddeltratamientocombinadodemetotrexatoyleflunomidaenpacientesconartritisreumatoidea
bdutipo_str Revistas
_version_ 1764819782216974337

Ejemplares similares